Neonatal, infant, and childhood growth following metformin versus insulin treatment for gestational diabetes: A systematic review and meta-analysis
Open accessThe DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Metformin is increasingly offered as an acceptable and economic alternative to insulin for treatment of gestational diabetes mellitus (GDM) in many countries. However, the impact of maternal metformin treatment on the trajectory of fetal, infant, and childhood growth is unknown. METHODS AND FINDINGS: PubMed, Ovid Embase, Medline, Web of Science, ClinicalTrials.gov, and the Cochrane database were systematically searched (from database inception to 26 February 2019). Outcomes of GDM-affected pregnancies randomised to treatment with metformin versus insulin were included (randomised controlled trials and prospective randomised controlled studies) from cohorts including European, American, Asian, Australian, and African women. Studies including pregnant women with pre-existing diabetes or non-diabetic women were excluded, as were trials comparing metformin treatment with oral glucose-lowering agents other than insulin. Two reviewers independently assessed articles for eligibility and risk of bias, and conflicts were resolved by a third reviewer. Outcome measures were parameters of fetal, infant, and childhood growth, including weight, height, BMI, and body composition. In total, 28 studies (n = 3,976 participants) met eligibility criteria and were included in the meta-analysis. No studies reported fetal growth parameters; 19 studies (n = 3,723 neonates) reported measures of neonatal growth. Neonates born to metformin-treated mothers had lower birth weights (mean difference -107.7 g, 95% CI -182.3 to -32.7, I2 = 83%, p = 0.005) and lower ponderal indices (mean difference -0.13 kg/m3, 95% CI -0.26 to 0.00, I2 = 0%, p = 0.04) than neonates of insulin-treated mothers. The odds of macrosomia (odds ratio [OR] 0.59, 95% CI 0.46 to 0.77, p < 0.001) and large for gestational age (OR 0.78, 95% CI 0.62 to 0.99, p = 0.04) were lower following maternal treatment with metformin compared to insulin. There was no difference in neonatal height or incidence of small for gestational age between groups. Two studies (n = 411 infants) reported measures of infant growth (18-24 months of age). In contrast to the neonatal phase, metformin-exposed infants were significantly heavier than those in the insulin-exposed group (mean difference 440 g, 95% CI 50 to 830, I2 = 4%, p = 0.03). Three studies (n = 520 children) reported mid-childhood growth parameters (5-9 years). In mid-childhood, BMI was significantly higher (mean difference 0.78 kg/m2, 95% CI 0.23 to 1.33, I2 = 7%, p = 0.005) following metformin exposure than following insulin exposure, although the difference in absolute weights between the groups was not significantly different (p = 0.09). Limited evidence (1 study with data treated as 2 cohorts) suggested that adiposity indices (abdominal [p = 0.02] and visceral [p = 0.03] fat volumes) may be higher in children born to metformin-treated compared to insulin-treated mothers. Study limitations include heterogeneity in metformin dosing, heterogeneity in diagnostic criteria for GDM, and the scarcity of reporting of childhood outcomes. CONCLUSIONS: Following intrauterine exposure to metformin for treatment of maternal GDM, neonates are significantly smaller than neonates whose mothers were treated with insulin during pregnancy. Despite lower average birth weight, metformin-exposed children appear to experience accelerated postnatal growth, resulting in heavier infants and higher BMI by mid-childhood compared to children whose mothers were treated with insulin. Such patterns of low birth weight and postnatal catch-up growth have been reported to be associated with adverse long-term cardio-metabolic outcomes. This suggests a need for further studies examining longitudinal perinatal and childhood outcomes following intrauterine metformin exposure. This review protocol was registered with PROSPERO under registration number CRD42018117503.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures















Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A follow-up study at 5-10 years showed that the offspring had higher BMI, weight-toheight ratios, waist circumferences, and a borderline increase in fat mass (88,89).”
From 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2024 (2024) · cites this paper as [88]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A meta-analysis demonstrated that metformin exposure resulted in smaller neonates with an acceleration of postnatal growth, resulting in higher BMI in childhood (88).”
From 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2024 (2024) · cites this paper as [88]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554
Hyperglycemia and adverse pregnancy outcomes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707943 · Cited by 5,563
Scottish Intercollegiate Guidelines Network
Twaddle, S., & Qureshi, S. (2005) · Evidence-based Healthcare and Public Health · doi:10.1016/j.ehbc.2005.09.008 · Cited by 4,084
Elective induction versus spontaneous labor after sonographic diagnosis of fetal macrosomia.
Combs, C. A., Singh, N. B., & Khoury, J. C. (1993) · PubMed · Cited by 2,500
OWEN, M. R., DORAN, E., & HALESTRAP, A. P. (2000) · Biochemical Journal · doi:10.1042/bj3480607 · Cited by 2,157
Association between postnatal catch-up growth and obesity in childhood: prospective cohort study
Ong, K. K. L. (2000) · BMJ · doi:10.1136/bmj.320.7240.967 · Cited by 1,668
Metformin versus insulin for the treatment of gestational diabetes
Rowan, J. A., Hague, W. M., Gao, W., Battin, M. R., & Moore, M. P. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707193 · Cited by 1,291
Prevalence of Gestational Diabetes and Risk of Progression to Type 2 Diabetes: a Global Perspective
Zhu, Y., & Zhang, C. (2016) · Current Diabetes Reports · doi:10.1007/s11892-015-0699-x · Cited by 1,260
Research works printed but not linked: 2
- Hamadani A, Zahid S, Butt ZB. Metformin versus insulin treatment in gestational diabetes in pregnancy and their effects on neonatal birthweight. Pak J Med Sci. 2017; 11: 914– 6.
- International Diabetes Federation. IDF diabetes atlas— 8th edition Brussels: International Diabetes Federation; 2017.
Cited by
Items 101–200 of 269
Thomakos, P., Kepaptsoglou, O., Korantzis, A., Trouva, A., Sklavounos, I., Trouvas, D., Taraoune, N., Barreto, C., & Zoupas, C. S. (2021) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.107914 · Cited by 8
Maternal diabetes negatively impacts fetal health
Corona, C. G., & Parchem, R. J. (2022) · Open Biology · doi:10.1098/rsob.220135 · Cited by 9
The metabolic response of human trophoblasts derived from term placentas to metformin
Tarry‐Adkins, J. L., Robinson, I. G., Pantaleão, L. C., Armstrong, J. L., Thackray, B. D., Holzner, L. M. W., Knapton, A. E., Virtue, S., Jenkins, B., Koulman, A., et al. (2023) · Diabetologia · doi:10.1007/s00125-023-05996-3 · Cited by 11
“Meta-analysis of clinical trials suggests that randomisation to metformin vs other treatments reduces birthweight independent of maternal glycaemic control in the context of gestational diabetes [15].”
BackgroundSelf-citationMcLennan, N.-M., Hazlehurst, J., Thangaratinam, S., & Reynolds, R. M. (2022) · European Journal of Endocrinology · doi:10.1530/eje-21-1046 · Cited by 13
Metformin inhibits OCT3-mediated serotonin transport in the placenta
Váchalová, V., Kumnova, F., Synova, T., Anandam, K. Y., Abad, C., Karahoda, R., & Štaud, F. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117399 · Cited by 7
Rawat, D., Gupta, Y., Yadav, A. K., Tembhre, M. K., Das, P., Bakkireddy, S., Singh, N., Sharma, K. A., Zangmo, R., Chandra, A., et al. (2024) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2024.103134 · Cited by 8
Bastian, B., Smithers, L. G., Davis, W. S., Pape, A., & François, M. E. (2022) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/ajo.13513 · Cited by 7
McCance, D. R., & Cassidy, L. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch71 · Cited by 9
Associations Between Gestational Weight Gain, Gestational Diabetes, and Childhood Obesity Incidence
Sneed, N. M., Heerman, W. J., Shaw, P. A., Han, K., Chen, T., Bian, A., Pugh, S., Duda, S. N., Lumley, T., & Shepherd, B. E. (2023) · Maternal and Child Health Journal · doi:10.1007/s10995-023-03853-8 · Cited by 8
“Metformin crosses the placenta and has been associated with lower birth weight, but higher BMI in mid-childhood (5–9 years) compared to treatment with insulin (Tarry-Adkins et al., 2019, 2020).”
Cantacorps, L., Zhu, J., Yagoub, S., Coull, B. M., Falck, J. E., Chesters, R., Ritter, K., Serrano-Lope, M. A., Tscherepentschuk, K., Kasch, L.-S., et al. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101860 · Cited by 6
“Supporting this is the evidence in humans that elevated rates of weight gain are seen in the children with metformin exposure [86].”
BackgroundMetformin in pregnancy and risk of abnormal growth outcomes at birth: a register-based cohort study
Brand, K. M. G., Thorén, R., Sõnajalg, J., Boutmy, E., Foch, C., Schlachter, J., Hakkarainen, K. M., & Saarelainen, L. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2022-003056 · Cited by 10
van Hoorn, E. G. M., Rademaker, D., van der Wel, A. W. T., DeVries, J. H., Franx, A., van Rijn, B. B., Kooy, A., Siegelaar, S. E., Roseboom, T. J., Ozanne, S. E., et al. (2023) · Diabetic Medicine · doi:10.1111/dme.15243 · Cited by 6
“20 Although evidence in humans is conflicting, 17,21–24 meta-analyses of randomized controlled trials suggested that maternal metformin treatment during pregnancy is associated with offspring adiposity by mid-childhood compared with placebo or insulin.”
BackgroundSelf-citationEditorial: Current and future trends in gestational diabetes diagnosis, care and neonatal outcomes
Frontino, G., Succurro, E., Corcoy, R., Scialabba, F., Poloniato, A., & Scavini, M. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1270472 · Cited by 6
Zimmerman, D. A., Briffa, J. F., Kong, D., Gravina, S., Daygon, V. D., Kumar, V., Moritz, K. M., Lim, L. Y., Teo, A. K. K., Chan, S., et al. (2025) · The Journal of Physiology · doi:10.1113/jp289453 · Cited by 5
“…outcomes in comparison to insulin (Zhao et al., 2020) but there remains hesitancy around the use of metformin during pregnancy because of the uncertainty around its mechanism of action as well as emerging evidence of perturbed offspring physiology (Nguyen et al., 2018; Tarry-Adkins et al., 2019).”
Metformin use and preeclampsia risk in women with diabetes: a two-country cohort analysis
Gordon, H. G., Salim, N., Tong, S., Walker, S. P., Silva, M. D., Cluver, C. A., Mehdipour, P., Hiscock, R. J., Sutherland, L. C., Doust, A. M., et al. (2024) · BMC Medicine · doi:10.1186/s12916-024-03628-0 · Cited by 8
“Other studies have found conflicting results concerning childhood BMI [32, 33], suggesting the need for further research to better characterise this potential relationship.”
ResultHiratsuka, V. Y., Reid, M., Chang, J. J., Jiang, L., Brega, A. G., Fyfe‐Johnson, A. L., Huyser, K. R., Johnson-Jennings, M., Conway, C., Steiner, J. F., et al. (2022) · Maternal and Child Health Journal · doi:10.1007/s10995-022-03536-w · Cited by 5
Big babies, small babies: metformin exposure in pregnancy
Kusinski, L. C., & Meek, C. L. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00034-7 · Cited by 5
Treatment of Diabetes in Pregnancy With Metformin
Newman, C., & Dunne, F. (2024) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000005705 · Cited by 5
Current Resources for Evidence-Based Practice, May 2020
Bovbjerg, M. L. (2020) · Journal of Obstetric, Gynecologic & Neonatal Nursing · doi:10.1016/j.jogn.2020.04.001 · Cited by 5
Sun, T., Meng, F., Zang, S., Li, Y., Zhang, R., Yu, Z., Huang, X., Wang, F., Zhang, L., & Liu, J. (2021) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-021-04066-z · Cited by 6
Muglia, L. J., Tong, S., Ozanne, S. E., & Benhalima, K. (2022) · BMC Medicine · doi:10.1186/s12916-022-02294-4 · Cited by 5
Self-citationMetformin in women with type 2 diabetes in pregnancy
Bailey, C. J. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30308-9 · Cited by 5
Araszkiewicz, A., Borys, S., Broncel, M., Budzynski, A. Z., Cyganek, K., Cypryk, K., CYRANKA, K. M., Czupryniak, L., Dąbrowski, M., Dzida, G. J., et al. (2026) · Current Topics in Diabetes · doi:10.5114/ctd/219306 · Cited by 5
Medications for Managing Preexisting and Gestational Diabetes in Pregnancy
Rickert, M. C., Caughey, A. B., & Valent, A. M. (2023) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2022.10.007 · Cited by 5
Treating obesity to optimize women’s health outcomes
Rubino, D., & Schon, S. B. (2025) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000002595 · Cited by 4
Noh, Y., Choe, S., & Shin, J. (2021) · Scientific Reports · doi:10.1038/s41598-021-83808-7 · Cited by 5
Gerbier, E., Favre, G., Maisonneuve, É., Ceulemans, M., Winterfeld, U., Dao, K., Schmid, C., Jenkinson, S. P., Niżnik, B., Baud, D., et al. (2023) · Journal of Diabetes Research · doi:10.1155/2023/4105993 · Cited by 6
“Other organisations, such as the American College of Obstetricians and Gynecologists (ACOG), do not endorse metformin use as a first-line therapy in GDM [18], possibly due to the metabolic consequences reported in children exposed to metformin in utero (lower birth weight and postnatal accelerated growth and higher mi…”
BackgroundAn update on gestational hyperglycemia diagnosis during the COVID-19 pandemic
Codina, M., Corcoy, R., & Goya, M. (2020) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2020.05.004 · Cited by 10
Jones, D. L., Rolfe, E. D. L., Rennie, K. L., Griep, L. M. O., Kusinski, L. C., Hughes, D. J., Brage, S., Ong, K. K., Beardsall, K., & Meek, C. L. (2021) · Nutrients · doi:10.3390/nu13041156 · Cited by 4
“For example, metformin use in pregnancy has been associated with lower birth weight but increased postnatal catch-up growth, but the consequences of this upon longer-term offspring cardiometabolic outcomes remain less clear [39,40].”
BackgroundCardiovascular outcome in 12‐month‐old male and female offspring of metformin‐treated obese mice
Schoonejans, J. M., Wilsmore, P., Mennitti, L. V., Wong, K. K., Ashmore, T. J., Garrud, T. A. C., Blackmore, H. L., Patey, O. V., Fernandez‐Twinn, D. S., Giussani, D. A., et al. (2025) · The Journal of Physiology · doi:10.1113/jp288696 · Cited by 3
Self-citationGestational diabetes: from pathogenesis to therapeutic intervention
Zhang, X., Chi, Y., Zhang, Z., Wang, Y., Yi, F., Wang, P., Liu, Y., & Hao, W. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02156-6 · Cited by 3
Dempsey, A., Mumby, C., Bernatavicius, G., Roberts, S. A., & Myers, J. (2020) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2020.1852209 · Cited by 4
Xie, E. F., Rodriguez, S. H., Xie, B., D’Souza, M., Gonnah, R., Sulakhe, D., & Skondra, D. (2023) · Frontiers in Pediatrics · doi:10.3389/fped.2023.1151239 · Cited by 4
Garvey, Z., Gupta, A., Taylor, N., Thirunavukkarasu, M., & Maulik, N. (2025) · Metabolites · doi:10.3390/metabo15030180 · Cited by 4
“Women receiving metformin treatment during pregnancy are less likely to require supplementary insulin [78,79].”
Daud, N. A. A., Mohiuddin, S. G., Ong, Y. P., Yusof, F. A. M., Yusoff, F., Harun, S. N., & Ghadzi, S. M. S. (2021) · Journal of Pharmacy And Bioallied Sciences · doi:10.4103/jpbs.jpbs_542_20 · Cited by 3
“[24] In terms of efficacy, metformin was also shown to be comparable to insulin therapy in controlling blood glucose level in GDM patients.”
Hegerty, C. K., & Ostini, R. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-069849 · Cited by 4
Management of Endocrinopathies During Pregnancy: A Systematic Review
Kirovakov, Z., Gyokova, E. H., Hinkova, N., & Stoilov, B. (2024) · Cureus · doi:10.7759/cureus.70554 · Cited by 3
Nugroho, B. S. (2025) · The International Journal of Medical Science and Health Research · doi:10.70070/gpgfhp26 · Cited by 3
D’Souza, A., Abdullahi, H., Badri, F., & Ibrahim, I. (2025) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-025-07869-6 · Cited by 5
“Two systematic reviews and meta-analyses, including 12 and 19 studies, respectively, have reported no difference in the risk of SGA between the metformin and insulin-treated groups [57, 58].”
Cichocka, E., & Gumprecht, J. (2022) · Medicina · doi:10.3390/medicina58030398 · Cited by 3
“9%) were complicated by hyperglycemia, despite the relatively low maternal age (<30 years) [1,4].”
BackgroundRamalho, D., Correia, S., Realista, R., Rocha, G., Alves, H., Almeida, L., Ferreira, E., Monteiro, S., Oliveira, M. J., Almeida, M. C., et al. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01931-x · Cited by 3
“The association of metformin use with higher SGA rates has been the subject of discussion as divergent conclusions have been emerging in recent years [7, 15].”
BackgroundResultHummel, M., Füchtenbusch, M., Battefeld, W., Bührer, C., Groten, T., Haak, T., Kainer, F., Kautzky‐Willer, A., Lechner, A., Meißner, T., et al. (2022) · Diabetologie und Stoffwechsel · doi:10.1055/a-1901-0499 · Cited by 3
Efectos perinatales de la metformina en diabetes gestacional
Lopez-Reyes, A., Escobedo-Aguirre, F., Lugo-Cruz, M. P., Jaén-Vento, L. A., & Macías‐Amezcua, M. D. (2020) · Clínica e Investigación en Ginecología y Obstetricia · doi:10.1016/j.gine.2020.09.002 · Cited by 3
Hummel, M., Füchtenbusch, M., Battefeld, W., Bührer, C., Groten, T., Haak, T., Kainer, F., Kautzky‐Willer, A., Lechner, A., Meißner, T., et al. (2023) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1946-3648 · Cited by 3
Nutrition for women and children—Are we doing the right things in the right way?
Persson, L. Å., Rasmussen, K. M., & Yang, H. (2019) · PLoS Medicine · doi:10.1371/journal.pmed.1002906 · Cited by 5
Paternal metformin use and congenital malformations in offspring
Gordon, H. G., Hastie, R. M., & Lindquist, A. (2024) · BMJ · doi:10.1136/bmj.q1792 · Cited by 3
Insulin therapy in diabetic kidney disease
Liu, Y., Zhao, C., Xiong, X., Yang, M., & Sun, L. (2021) · Diabetic Nephropathy · doi:10.2478/dine-2022-0006 · Cited by 2
Shuffrey, L. C., Pini, N., Mei, H., Rodríguez, C., Gimenez, L. A., Barbosa, J. R., Rodriguez, D. J., Rayport, Y. K., Sania, A., Monk, C. E., et al. (2024) · Developmental Psychobiology · doi:10.1002/dev.70014 · Cited by 2
Reproductive outcomes in female mice offspring due to maternal metformin treatment
Velázquez, C., Herrero, Y., Prost, K., Bordaquievich, M., Neira, M., Parborell, F., & Abramovich, D. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123416 · Cited by 2
MOORE, L. G., Wesolowski, S. R., Lorca, R. A., & Julian, C. G. (2025) · Acta Physiologica · doi:10.1111/apha.70093 · Cited by 2
“While metformin has been shown to improve cardiovascular outcomes in type-2 diabetes [157], a meta-analysis of over 30 studies on the offspring of mothers who had been treated with metformin indicated that the incidence of FGR had increased, not decreased [158–162].”
Zhang, W., Ren, L., Du, J., Sun, R., Zhao, W., Song, X., Jiang, S., Wang, Z., & Wang, W. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2025.1737337 · Cited by 2
“The comparable SGA risk between metformin and insulin aligns with a previous meta-analysis, reinforcing the reliability of this finding (32).”
Metformin therapy in pregnancy [Zastosowanie metforminy w ciąży]
Krupej, J., Cichocka, E., Kędzierski, L., Okopień, B., & Gumprecht, J. (2020) · Endokrynologia Polska · doi:10.5603/ep.a2020.0016 · Cited by 2
Beyond Glucose: The Overlooked Role of Lipids in Gestational Diabetes
Scairati, R., Laudisio, D., Imperatore, O., Masulli, M., & Colao, A. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104758 · Cited by 2
Diagnosis and therapy of gestational diabetes
Salmanowicz, M., Nowicka, P., Banach, B., & Kukowka, A. (2022) · Farmacja Polska · doi:10.32383/farmpol/152113 · Cited by 2
Diabetes During Pregnancy: Neonatal and Childhood Complications
van der Beek, E. M. (2022) · Springer eBooks · doi:10.1007/978-3-030-89243-2_17 · Cited by 2
Cardiometabolic and Renal DOHaD Outcomes in Offspring of Complicated Pregnancy
Giussani, D. A., Reynolds, R. M., Leeson, P., Moritz, K. M., Bertram, J. F., & Ozanne, S. E. (2022) · Cambridge University Press eBooks · doi:10.1017/9781009272254.011 · Cited by 3
Self-citationMetformin – régi motoros erősebb motorral
Winkler, G. (2022) · Diabetologia Hungarica · doi:10.24121/dh.2022.24 · Cited by 2
Adamczewski, H. (2023) · Die Diabetologie · doi:10.1007/s11428-023-01071-y · Cited by 3
Alobaidy, Z., Alammar, H., & Al-Harmooshee, M. B. H. (2023) · Journal of Biomedicine and Biochemistry · doi:10.57238/jbb.2023.7061.1045 · Cited by 2
“It reduces appetite and calorie intake by reducing hepatic glucose production and increasing tissue sensitivity to insulin [25, 26].”
BackgroundBiagioni, E. M., ROWE, J. C., Yendamuri, S., Wisseman, B., Zheng, D., Zhang, G., Muoio, D. M., DeVente, J., Fisher‐Wellman, K. H., Neufer, P. D., et al. (2025) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00428.2024 · Cited by 2
Liu, D., Chen, X., Wang, Q., Pan, X., Wei, X., Wang, B., Wang, Y., Xue, X., & Lu, C. (2025) · Precision medication. · doi:10.1016/j.prmedi.2025.100035 · Cited by 3
Boyd, A. R., & Conway, D. (2023) · Wiley eBooks · doi:10.1002/9781119636540.ch19 · Cited by 2
Das metabolische Syndrom und Schwangerschaft
Mayer-Pickel, K. I. (2020) · Journal für Gynäkologische Endokrinologie/Österreich · doi:10.1007/s41974-020-00169-1 · Cited by 1
“Mittlerweile gibt es auch einige Hinweise, dass Metformin das Risiko einer fetalenMakrosomie reduziert und damit inweitererFolgedieRateanKaiserschnitten senkt [23, 24].”
BackgroundOnah, P. O., Idoko, C. C., & Abdulateef, S. (2023) · International Journal of Integrated Health Sciences · doi:10.15850/ijihs.v11n1.2840 · Cited by 1
Díez, J. J., Anda, E., Bretón, I., González, C., Miguélez, M., Zugasti, A., & Fernández, A. (2024) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2024.11.001 · Cited by 1
Li, M., Li, L., Liu, X., Yang, T., Gao, J., Wu, A., Hua, Z., & Wang, L. (2024) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2024.01066 · Cited by 1
Díez, J. J., Anda, E., Lesmes, I. B., González, C., Miguélez, M., Zugasti, A., & Fernández, A. (2025) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2025.101531 · Cited by 4
Treatment of type 2 diabetes in pregnancy: Do we need to use metformin?
Fu, J. M., & Feig, D. S. (2025) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2025.102027 · Cited by 1
Su, Y., Sun, M., Huang, Q., Xu, L., Zhao, C., Xu, F., Tao, N., & Yang, Y. (2026) · Journal of International Medical Research · doi:10.1177/03000605261443077 · Cited by 1
“25 Cinnamon supplementation substantially decreased fasting plasma glucose levels, improved insulin resistance, and decreased HbA1c levels in patients with type 2 diabetes, according to another meta-analysis that included 24 RCTs.”
Hummel, M., Füchtenbusch, M., Battefeld, W., Bührer, C., Groten, T., Haak, T., Kainer, F., Kautzky‐Willer, A., Lechner, A., Meißner, T., et al. (2023) · Diabetologie und Stoffwechsel · doi:10.1055/a-2076-0040 · Cited by 1
Asatiani, N., Kurashvili, R. B., & Shelestova, E. (2024) · Series of Clinical and Medical Case Reports and Reviews · doi:10.54178/2993-3579.v2i1a2026 · Cited by 2
Saha, S., & Saha, S. (2020) · Dubai Diabetes and Endocrinology Journal · doi:10.1159/000507244 · Cited by 2
Painter, R. C., Finken, M. J. J., & van Rijn, B. B. (2020) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2020.07.006 · Cited by 1
Antidiabetic compounds 8a, 8b, 8k, and 9h enhance insulin secretion: activity and mechanism
Li, H., Zhang, J., Fu, Y., Zhang, Y., Zhang, C., Sun, X., Wu, F., & He, J. N. (2020) · Endocrine · doi:10.1007/s12020-020-02537-5 · Cited by 2
O uso da metformina no tratamento do Diabetes Mellitus Gestacional
Duarte, B. R., CALIAN, G. S., RODRIGUES, L. A., ALBERTINO, N. C. N., SANTOS, P. P. R. D., & Vasconcellos, M. (2020) · Multidisciplinary Reviews · doi:10.29327/multi.2021003 · Cited by 1
“(Tarry-Adkins et al 2019).”
BackgroundInfluentialNeue Aspekte aus der S2e-Leitlinie: Diabetes bei Kinderwunsch – engmaschig überwachen
Füchtenbusch, M., Hummel, M., Battefeld, W., Bührer, C., Groten, T., Haak, T., Kainer, F., Kautzky‐Willer, A., Lechner, A., Meißner, T., et al. (2022) · Deutsches Ärzteblatt · doi:10.3238/persdia.2022.01.21.02 · Cited by 1
Anastasiou, E., & Paschou, S. Α. (2022) · Springer eBooks · doi:10.1007/978-3-030-89243-2_14 · Cited by 1
Consecuencias sobre el feto debido al uso de meformina en diabetes gestacional
Barrios, R. A. L., Cervantes, I. D. E., Vasquez, C. A. G., Calderón, A. M. M., & Vargas, S. A. S. (2022) · Ciencia Latina Revista Científica Multidisciplinar · doi:10.37811/cl_rcm.v6i4.2955 · Cited by 1
Clinical Application of Metformin Use in Anhui Province, China: A Cross-Sectional Study
Chen, L., Chen, Q., Chen, X., Zhu, P., Chen, M., Wang, W., Ye, S., & Zheng, M. S. (2023) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s397061 · Cited by 1
Hummel, M., Füchtenbusch, M., Battefeld, W., Bührer, C., Groten, T., Haak, T., Kainer, F., Kautzky‐Willer, A., Lechner, A., Meißner, T., et al. (2024) · Die Diabetologie · doi:10.1007/s11428-024-01189-7 · Cited by 1
Konservative und medikamentöse Therapie des Gestationsdiabetes mellitus
Kleinwechter, H. J., & Laubner, K. (2019) · Der Diabetologe · doi:10.1007/s11428-019-00543-4
Mate, A., Blanca, A. J., Salsoso, R., Toledo, F., Stiefel, P., Sobrevía, L., & Vázquez, C. M. (2020) · Current Vascular Pharmacology · doi:10.2174/157016111804200507091851
Atenção individual e coletiva à saúde materna e infantil no cenário brasileiro
Jacob, L. M. D. S., da Silva, A. D. J., Feijão, A. M. L., dos Santos, A. H., de França, A. M. B., Júnior, A., da Silva, A. P., Araújo, A. M., Martins, A. B. T., Alcantara, A. B., et al. (2020) · Editora Inovar eBooks · doi:10.36926/editorainovar-978-65-86212-51-8 · Cited by 3
Hipoglicemiantes orales en el tratamiento sobre Diabetes Mellitus tipo 2: Metformina
Garmendia-Lorena, F. (2020) · Diagnóstico · doi:10.33734/diagnostico.v59i1.202
Sterpetti, S., & Buzzetti, R. (2021) · L Endocrinologo · doi:10.1007/s40619-021-00826-3
Kawaharada, R., & Nakamura, A. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.100117 · Cited by 1
Using Resistance Training in Women with Gestational Diabetes Mellitus to Improve Glucose Regulation
Allman, B. R., McDonald, S. M., May, L. E., Kinsey, A. W., & Børsheim, E. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.101076 · Cited by 1
An Updated Review of the Gestational Diabetes
Moori, M. H. (2021) · Disease and Diagnosis · doi:10.34172/ddj.2021.22
“Tarry-Adkins et al (39) have recently published a metaanalysis indicating that insulin therapy could reduce the birth of neonates diagnosed large for gestational age (LGA) and fetal macrosomia significantly.”
BackgroundManaging Gestational Diabetes During and After Pregnancy
Egan, A. M., & Dunne, F. (2021) · Wiley eBooks · doi:10.1002/9781119603207.ch6 · Cited by 1
Diabète gestationnel : prise en charge en 2020 et risque futur
Renson, V., Grandfils, S., & Philips, J. (2020) · JMIG · doi:10.53738/revmed.2020.16.703.1498 · Cited by 1
Amarawardena, M., Silva, N. D., Weerasena, L., Jeyashree, K., Mahanama, S., Udesh, T., Selvaratnam, K., & Silva, P. (2022) · Research Square · doi:10.21203/rs.3.rs-1426733/v1
Sun, T., Meng, F., Zang, S., Li, Y., Zhang, R., Yu, Z., Huang, X., Wang, F., Zhang, L., & Liu, J. (2021) · Research Square · doi:10.21203/rs.3.rs-330032/v1
Oral Anti-Hyperglycemic Agents
Mintziori, G., & Goulis, D. G. (2022) · Springer eBooks · doi:10.1007/978-3-030-89243-2_13
Chatzakis, C., Sotiriadis, A., Gerede, A., Dinas, K. D., & Nicolaides, K. H. (2022) · Springer eBooks · doi:10.1007/978-3-030-89243-2_16
Hummel, M., Füchtenbusch, M., Battefeld, W., Bührer, C., Groten, T., Haak, T., Kainer, F., Kautzky‐Willer, A., Lechner, A., Meißner, T., et al. (2022) · Diabetes aktuell · doi:10.1055/a-1976-8965
Hummel, M., Füchtenbusch, M., Battefeld, W., Bührer, C., Groten, T., Haak, T., Kainer, F., Kautzky‐Willer, A., Lechner, A., Meißner, T., et al. (2022) · Die Diabetologie · doi:10.1007/s11428-022-00988-0
“Gewichtserhaltung bei Frauen mit einem BMI >35kg/m2 fehlen [65].”
Metformin use in pregnancy: efficacy, safety, and potential benefits
Sorice, G. P., Caporusso, M., Cignarelli, A., Perrini, S., Natalicchio, A., & Giorgino, F. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-022-01991-4
Pisani, L. P., & Ozanne, S. E. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-823937-7.00005-5
Self-citationHipoglucemiantes orales en el control metabólico de la diabetes gestacional.
Lazo-Feijoo, L. A., & Campoverde, L. H. M. (2023) · MQRInvestigar · doi:10.56048/mqr20225.7.3.2023.2454-2482
Metadata
- Authors
- Tarry-Adkins, J. L., Aiken, C. E., & Ozanne, S. E.
- Affiliations
- University of Cambridge (GB)
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2019-08-06
- Volume
- 16
- Issue
- 8
- Pages
- e1002848
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC6684046
- OpenAlex
- W2963238421
- Cited by
- 251
- References
- 77
- Citations by year
- 2026: 25 · 2025: 28 · 2024: 37 · 2023: 59 · 2022: 35 · 2021: 41 · 2020: 23 · 2019: 3
- FWCI
- 4.03
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Apollo (University of Cambridge) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Apollo
- Funders
- British Heart Foundation (RG/17/12/33167)
- Medical Research Council (MC_ UU_12012/4)
- Addenbrooke's Charitable Trust, Cambridge University Hospitals (GB)
- Isaac Newton Trust
- Wellcome Trust
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Birth, Development, and Health
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Keywords
- gestational diabetes mellitus, metformin, insulin therapy, neonatal growth, infant growth, child growth, birth weight, macrosomia, large for gestational age, small for gestational age, body composition, fetal growth, childhood obesity risk, child height, child weight gain, childhood adiposity
- MeSH terms
- Child Development, Child, Preschool, Female, Humans, Hypoglycemic Agents, Infant, Infant, Newborn, Insulin, Metformin, Pregnancy, Diabetes, Gestational
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.